Iodine as a Cytological Stain.

F. B. Adamstone,A. Taylor

IF: 56.9

Science

Abstract:

What problem does this paper attempt to address?

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)

Philip Turton,Dima El-Sharkawi,Iain Lyburn,Bhupinder Sharma,Preethika Mahalingam,Suzanne D Turner,Fiona MacNeill,Laura Johnson,Stephen Hamilton,Cathy Burton,Nigel Mercer

DOI: https://doi.org/10.1016/j.bjps.2020.10.064

Abstract:Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK) negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimize the need for systemic treatments, reduce morbidity and the risk of poor outcomes. These guidelines provide an evidence-based and systematic framework for the assessment and treatment of patients with suspected or proven BIA-ALCL and are aimed at all clinicians involved in the care of people with breast implants.
UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

Philip Turton,Dima El‐Sharkawi,Iain Lyburn,Bhupinder Sharma,Preethika Mahalingam,Suzanne D. Turner,Fiona MacNeill,Laura Johnson,Stephen Hamilton,Cathy Burton,Nigel Mercer

DOI: https://doi.org/10.1111/bjh.17194

2020-11-22

British Journal of Haematology

Abstract:<p>Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is an uncommon T‐cell non‐Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA‐ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri‐implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the aspirated peri‐implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK)‐negative and strongly positive for CD30. BIA‐ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en‐bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimise the need for systemic treatments, reduce morbidity and the risk of poor outcomes.</p>

hematology
Effect of Tin Protoporphyrin on the Excretion Rate of Carbon Monoxide in Newborn Rats After Hematoma Formation

Andrew M. Posselt,B. Cowan,Linda K. Kwong,H. Vreman,David K. Stevenson

DOI: https://doi.org/10.1097/00005176-198508000-00027

1985-08-01

Abstract:Summary This study evaluated the efficacy of tin protoporphyrin (TP), a competitive inhibitor of heme oxygenase, in suppressing the total body excretion rate of carbon monoxide (CO), an index of total bilirubin formation, in neonatal rats with artificially created hematomas. Wistar rat litters less than 12 h old were each divided into three groups of similar weight and treated as follows: (a) saline control (S); (b) hematoma, 80 μl blood (H); (c) TP, 65 (μmol/kg, and hematoma (TP H). CO excretion of the H group increased rapidly after hematoma formation, reaching a maximum value of 79 ± 4 SE μl/kg/h 25 h later. Treatment with TP did not affect the pattern of CO excretion or its magnitude (78 ± 2 SE μl/kg/h, 25 h posthematoma). The S group showed no increase in CO excretion at this time (40 ± 2 SE μl/kg/h). At the conclusion of the experiment (45 h posthematoma), the plasma total bilirubin levels were slightly lower in the TP H rats (1.0 ± 0.1 SE mg/dl) than in H rats (1.2 ± 0.1 SE mg/dl). The S rats had a plasma total bilirubin concentration of 0.8 ± 0.1 SE mg/ dl. The hepatic and splenic heme oxygenase activities were decreased by 61% (p < 0.001) and 48% (p < 0.05), respectively, in the TP H rats as compared to the H rats. The S and H rats had similar enzyme activities. The results of this study suggest that though single dose TP decreased tissue heme oxygenase activity, it did not significantly affect total bilirubin formation.
Radiography of the hip bone.

C. Bridgman

Abstract:
Transition from traveling to standing waves in the 4:1 resonant Belousov-Zhabotinsky reaction.

B. Marts,Anna L. Lin

DOI: https://doi.org/10.1103/PHYSREVE.77.026211

2008-02-14

Abstract:We report a transition from traveling to standing domain walls in a parametrically forced two-dimensional oscillatory Belousov-Zhabotinsky chemical reaction in 4:1 resonance. Our experimental results demonstrate spatiotemporal solutions not predicted by previous analytic results of the complex Ginzburg-Landau amplitude equation and numerical results from reaction-diffusion models. In addition to the stationary pi fronts at high forcing amplitudes, the 4:1 resonant patterns we observe include stationary pi/2 fronts.
Current Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Chehak Bewtra,Pankaj Gharde

DOI: https://doi.org/10.7759/cureus.30516

2022-10-20

Cureus

Abstract:Every year, breast implants are inserted worldwide for reconstructive or aesthetic reasons. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rather uncommon type of T cell lymphoma that is positive for the CD30 biomarker. Despite being far more common than other primary breast lymphomas, BIA-ALCL has a very low incidence. Textured types of implants have been linked to almost all cases. The majority of patients have a favorable prognosis after the removal of implants and capsules. Nevertheless, the chance of a fatal outcome is higher with capsular invasion and tumor bulk. Although the exact cause of BIA-ALCL is unknown, it has been suggested that persistent infections or toxins related to the implants may play a role. Therefore, physicians must be aware of breast implants' rare but potentially significant side effects. Before surgery, patients with verified instances should be directed to a breast medical oncologist or lymphoma specialist for oncologic assessment. Total en-bloc capsulectomy, a surgical procedure that removes the implant and the surrounding capsule, is usually adequate. In other cases, a late diagnosis necessitates more invasive surgery and systemic therapies, which, while typically effective, have been linked to poor outcomes and even fatalities. Since it is a recently described entity and the "denominator" (i.e., the total number of breast implant procedures) is unknown, it is challenging to determine the risk of development. In this review, we hope to emphasize the elements of etiology, demography, clinical features, and current treatment approaches for BIA-ALCL. In doing so, we hope to increase the medical professional's knowledge of the recognition and treatment of BIA-ALCL.
Psychologic testing in evaluating and understanding organic brain damage and the effects of drugs in children.

S. Santostefano

DOI: https://doi.org/10.1016/S0022-3476(63)80048-7

IF: 2.99

1963-05-01

Jornal de Pediatria

Abstract:
The relationship of average backfat thickness of feedlot steers to performance Roundup 2004

J. Brethour

Abstract:The length of time to keep cattle on feed that maximizes profits is determined by the point when incremental costs equal incremental increases in animal value. The primary cost in a cattle feeding enterprise is ration expense, so in order to effectively project optimal marketing time it is necessary to be able to determine future feed conversion. It is widely considered that feed conversion is related to composition of gain. That is because fat tissue contains only about 10% water compared to 73% water in muscle and the caloric value of a gram of fat is 69% more than that of a gram of protein. Consequently, it has been assumed that the energetic cost of fat accretion is much more than protein.
Current Progress in Breast Implant-Associated Anaplastic Large Cell Lymphoma

Yichen Wang,Qi Zhang,Yufang Tan,Wenchang Lv,Chongru Zhao,Mingchen Xiong,Kai Hou,Min Wu,Yuping Ren,Ning Zeng,Yiping Wu

DOI: https://doi.org/10.3389/fonc.2021.785887

IF: 4.7

2022-01-06

Frontiers in Oncology

Abstract:Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is an uncommon type of T-cell lymphoma. Although with a low incidence, the epidemiological data raised the biosafety and health concerns of breast reconstruction and breast augmentation for BIA-ALCL. Emerging evidence confirms that genetic features, bacterial contamination, chronic inflammation, and textured breast implant are the relevant factors leading to the development of BIA-ALCL. Almost all reported cases with a medical history involve breast implants with a textured surface, which reflects the role of implant surface characteristics in BIA-ALCL. With this review, we expect to highlight the most significant features on etiology, pathogenesis, diagnosis, and therapy of BIA-ALCL, as well as we review the physical characteristics of breast implants and their potential pathogenic effect and hopefully provide a foundation for optimal choice of type of implant with minimal morbidity.

oncology
Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research

Anand K Deva,Suzanne D Turner,Marshall E Kadin,Mark R Magnusson,H Miles Prince,Roberto N Miranda,Giorgio G Inghirami,William P Adams Jr

DOI: https://doi.org/10.3390/cancers12123861

2020-12-21

Abstract:Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma. Where implant history is known, all confirmed cases to date have occurred in patients with exposure to textured implants. There is a spectrum of disease presentation, with the most common occurring as a seroma with an indolent course. A less common presentation occurs as locally advanced or, rarely, as metastatic disease. Here we review the immunological characteristics of BIA-ALCL and potential triggers leading to its development. BIA-ALCL occurs in an inflammatory microenvironment with significant lymphocyte and plasma cell infiltration and a prominent Th1/Th17 phenotype in advanced disease. Genetic lesions affecting the JAK/STAT signaling pathway are commonly present. Proposed triggers for the development of malignancy include mechanical friction, silicone implant shell particulates, silicone leachables, and bacteria. Of these, the bacterial hypothesis has received significant attention, supported by a plausible biologic model. In this model, bacteria form an adherent biofilm in the favorable environment of the textured implant surface, producing a bacterial load that elicits a chronic inflammatory response. Bacterial antigens, primarily of Gram-negative origin, may trigger innate immunity and induce T-cell proliferation with subsequent malignant transformation in genetically susceptible individuals. Although much remains to be elucidated regarding the multifactorial origins of BIA-ALCL, future research should focus on prevention and treatment strategies, recognizing susceptible populations, and whether decreasing the risk of BIA-ALCL is possible.
Our Experience in Diagnosing and Treating Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Gon Shoham,Oriana Haran,Roei Singolda,Ehab Madah,Ada Magen,Orit Golan,Tehillah Menes,Ehud Arad,Yoav Barnea

DOI: https://doi.org/10.3390/jcm13020366

IF: 3.9

2024-01-10

Journal of Clinical Medicine

Abstract:Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell lymphoma detected in association with textured implants. It presents as a fluid accumulation around the implant, usually years after the implantation. We present our experience in diagnosing and treating four patients with BIA-ALCL, each widely differing from the other. Data on patients' surgical history, relevant medical information, and findings on pathological slides were retrieved from their medical charts and retrospectively reviewed. Each of the four patients was diagnosed with BIA-ALCL, one after breast augmentation, one after breast reconstruction with an implant, one after breast reconstruction with a latissimus dorsi flap and implant, and the fourth after the removal of breast implants. The cases were presented to a multidisciplinary team and subsequently underwent surgery. All four are currently free of tumors, as established by a negative follow-up via positron emission tomography-computed tomography. Although the incidence of BIA-ALCL is rare, these cases emphasize the need to rule out the diagnosis of BIA-ALCL in patients with textured implants or a history of implanted textured devices who present with symptoms such as late seroma or peri-implant mass. This pathology is typically indolent and slow-growing and heightened awareness for an early diagnosis could lead to quicker intervention and enhanced patient management.

medicine, general & internal
Breast implant-associated anaplastic large-cell lymphoma: A series of two case reports diagnosed by cytopathology

Morgan Hrones,Malini Harigopal,Mina Xu,Rita Abi-Raad

DOI: https://doi.org/10.1002/dc.25052

Abstract:Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma with a good prognosis. It occurs in association with textured breast implants. Its most common presentation is a late-onset peri-implant effusion. We present two cases of BIA-ALCL diagnosed by cytopathological examination of the fluid collection and describe the cytopathologic findings. Both patients were disease free after implant removal. This report highlights the contribution of the cytopathologic analysis to early diagnosis and definite treatment of BIA-ALCL.
Enhanced N2 dissociation on Ru-loaded inorganic electride.

N. Kuganathan,H. Hosono,A. Shluger,P. Sushko

DOI: https://doi.org/10.1021/ja410925g

IF: 15

2014-01-31

Journal of the American Chemical Society

Abstract:Electrides, i.e. salts in which electrons serve as anions, are promising materials for lowering activation energies of chemical reactions. Ab initio simulations are used to investigate the effect of the electron anions in a prototype mayenite-based electride (C12A7:e(-)) on the mechanism of N2 dissociation. It is found that both atomic and molecular nitrogen species chemisorb on the electride surface and become negatively charged due to the electron transfer from the substrate. However, charging alone is not sufficient to promote dissociation of N2 molecules. In the presence of Ru, N2 adsorbs with the formation of a cis-Ru2N2 complex and the N-N bond weakens due to both the electron transfer from the substrate and interaction with Ru. This complex transforms into a more stable trans-Ru2N2 configuration, in which the N2 molecule is dissociated, with the calculated barrier of 116 kJ mol(-1) and the overall energy gain of 72 kJ mol(-1). In contrast, in the case of the stoichiometric mayentie, the cis-Ru2N2 is ~34 kJ mol(-1) more stable than the trans-Ru2N2, while the cis-trans transition has a barrier of 192 kJ mol(-1). Splitting of N2 is promoted by a combination of the strong electron donating power of C12A7:e(-), ability of Ru to capture N2, polarization of Ru clusters, and electrostatic interaction of negatively charged N species with the surface cations.
Breast Implant-associated Anaplastic Large Cell Lymphoma - a Systematic Review with Pooled Analysis

M Co,T H Chan,K F S Ip,H M G Lam,G Y Ling,K W K Ma,C T Poon,O L Yiu,H T Yu,A Kwong

DOI: https://doi.org/10.1016/j.clon.2020.05.019

Abstract:The association of breast implants and anaplastic large cell lymphoma (BIA-ALCL) was first described in 1997. Such an association has aroused public health concerns on breast implant safety. A systematic review was carried out with a pooled analysis of data. In total, 674 non-duplicate articles were retrieved; 77 articles were included for data extraction; 395 patients were identified for analysis. The median age at the time of diagnosis was 52 years. Implant texture was described in 201 (50.9%) patients; all 201 patients had a textured implant. The median time from the last implant insertion to diagnosis was 7.5 years. Most patients presented with seroma (67.1%, n = 265), 20.5% of patients presented with breast mass (n = 81). Patients with a breast mass at presentation, lymphadenopathy and those without seroma had more disseminated disease (P < 0.001). 73.2% of patients (n = 289) opted for primary surgery, among which 68.6% (n = 271) received removal of the implant, 61% (n = 241) received capsulectomy and 2% (n = 8) received mastectomy. Of note, 5.3% (n = 21) had reinsertion of an implant after primary surgery. Non-surgical modalities included chemotherapy, radiotherapy and haematopoietic stem cell transplant. The median follow-up interval was 2 years (range 0-14.5 years). Seventeen patients (4.3%) had recurrence of BIA-ALCL and 195 patients (49.4%) did not. The median duration to first recurrence was 1 year (range 1-3 years). Long-term clinical outcome was not reported in 183 patients. BIA-ALCL is an indolent disease that presents with seroma after implant insertion. A high index of suspicion is needed for early diagnosis and treatment.
Open loop compensation for the eddy current effect in the APS storage ring vacuum chamber

Y. Chung,J. Bridges,L. Emery,G. Decker

DOI: https://doi.org/10.2172/378786

1990-05-30

Abstract:Results of the effort to counter the effect due to the finite inductance of the magnet and the eddy current in the 1/2-in-thick aluminum storage ring vacuum chamber are presented. The amplitude attenuation and the phase shift of the correction magnet field inside the APS storage ring vacuum chamber were measured. A circuit to compensate for this effect was then inserted between the signal source and the magnet power supply. The amplitude was restored with an error of less than 20% of the source signal amplitude and the phase shift was reduced from 80 degrees to 12 degrees at 10 Hz. Incorporation of this circuit in the closed-loop feedback scheme and the resulting beneficial effect in the closed-orbit stabilization is discussed.<<ETX>>
Breast implant-associated anaplastic large cell lymphoma: where hematology and plastic surgery meet

Maria Magdalena Joks,Krystian Czernikiewicz,Łukasz Mazurkiewicz,Monika Joks,Andrzej Balcerzak,Renata Kroll-Balcerzak,Joanna Rupa–Matysek

DOI: https://doi.org/10.1016/j.clml.2024.05.008

2024-05-10

Abstract:Breast implant insertion for breast reconstruction or breast augmentation is a developing procedure, with high demand worldwide – being the 2 nd most common plastic surgery in the US as of 2022. Breast – implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is T-cell, non-Hodgkin lymphoma, typically CD30+, ALK-, presenting with fluid collection in the inner aspect of the peri-implant capsule in most patients, with the onset exceeding one-year after implantation. The mean time between breast implant insertion and BIA - ALCL development is 7-10 years. The main risk factor is the use of textured implants because of their susceptibility to triggering local inflammation and immune stimulation finally leading to lymphoproliferation. Genetic predispositions to hereditary breast cancer increase the risk of disease development as well. BIA-ALCL seems to be underestimated in many countries and the initial symptom–seroma might be overlooked and misdiagnosed. Despite its rarity, the awareness of the disease should be improved among patients and medical professionals. This paper summarizes epidemiology, etiopathogenesis, differential diagnosis, and treatment - both surgical and hematological approaches.

oncology,hematology
Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Why Must We Learn About It?

Letícia Morais Coelho de Oliveira Sermoud,Sérgio Romano,Maurício Chveid,Gilberto Luiz da Silva Amorim

DOI: https://doi.org/10.1200/JGO.19.00224

Abstract:Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, breast implant-associated T-cell lymphoma in which CD30 is expressed and anaplastic lymphoma kinase (ALK) expression is absent. However, despite the low risk of developing the disease, more information on BIA-ALCL is necessary, because the number of women with breast implants has been increasing worldwide; Brazil is one of the main markets for this type of implant. The objectives of this review are to clarify the issue of BIA-ALCL occurrence after risk-reducing mastectomy, to show the importance of this disease, and to raise awareness among the medical community about this rare pathologic condition. In 2016, BIA-ALCL was included by WHO in the new classification of lymphomas, and this demonstrates the attention that medical entities should give to this disease. Thus, awareness about BIA-ALCL must be broadened among the medical societies and regulatory authorities, both to foster better approaches to this disease, which should be evaluated in a multidisciplinary manner, and to provide better knowledge among health care professionals and the target population about the use of implants.
NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Mark W. Clemens,Steven M. Horwitz

DOI: https://doi.org/10.1093/asj/sjw259

2017-02-10

Aesthetic Surgery Journal

Abstract:Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Comprehensive Cancer Network (NCCN) annually publishes Clinical Practice Guidelines for Non-Hodgkin Lymphomas. For the first time, BIA-ALCL management will be included which signifies an important and needed guideline addition. The new BIA-ALCL guideline was achieved by a consensus of lymphoma oncologists, plastic surgeons, radiation oncologists, and surgical oncologists. NCCN guidelines focus on the diagnosis and management throughout the stages of many lymphoma subtypes based upon the most current data available. This article summarizes the essential recommendations and optimal therapeutic strategies of the NCCN guidelines critical to the plastic surgery community. We encourage international adoption of these BIA-ALCL treatment standards by our specialty societies across the oncology and surgery disciplines.

surgery
Breast Implant Associated Anaplastic Large Cell Lymphoma: Evidence-Based Consensus Conference Statement From The American Association of Plastic Surgeons

Mark W Clemens,Terence Myckatyn,Arianna Di Napoli,Andrew L Feldman,Elaine S Jaffe,Cara L Haymaker,Steven M Horwitz,Kelly K Hunt,Marshall E Kadin,Colleen M McCarthy,Roberto N Miranda,H Miles Prince,Fabio Santanelli di Pompeo,Sari D Holmes,Linda G Phillips,Mark W. Clemens,Andrew L. Feldman,Elaine S. Jaffe,Cara L. Haymaker,Steven M. Horwitz,Kelly K. Hunt,Marshall E. Kadin,Colleen M. McCarthy,Roberto N. Miranda,H. Miles Prince,Sari D. Holmes,Linda G. Phillips

DOI: https://doi.org/10.1097/prs.0000000000011370

2024-02-27

Plastic & Reconstructive Surgery

Abstract:Background: In the absence of high-quality evidence, there is a need to provide guidelines and multidisciplinary consensus recommendations on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The purpose of this expert consensus conference was to evaluate the existing evidence regarding the diagnosis, and management of BIA-ALCL caused by textured implants. The aim is to provide evidence-based recommendations regarding the management and prevention of BIA-ALCL. Methods: A comprehensive search was conducted in the MEDLINE, Cochrane Library, and Embase databases, supplemented by manual searches of relevant English language articles and "related articles" sections. Studies focusing on breast surgery and lymphoma associated with breast implants were included for analysis. Meta-analyses were performed and reviewed by experts selected by the American Association of Plastic Surgeons by a Delphi consensus method. Results: 840 articles between January 2011 and January 2023 were initially identified and screened. Full-text of 188 articles were assessed. An additional 43 articles were excluded for focus, and 145 articles were included in the synthesis of results, with 105 of them being case reports or case series. The analysis encompassed a comprehensive examination of the selected articles to determine the incidence, risk factors, clinical presentation, diagnostic approaches, and treatment modalities related to BIA-ALCL. Conclusions: Plastic surgeons should be aware of the elevated risks by surface type, implement appropriate patient surveillance, and follow the recommendations outlined in this statement to ensure patient safety and optimize outcomes. Ongoing research on pathogenesis, genetic drivers, and preventative and prophylactic measures is crucial for improving patient care.

surgery

Iodine as a Cytological Stain.

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG)

UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

Effect of Tin Protoporphyrin on the Excretion Rate of Carbon Monoxide in Newborn Rats After Hematoma Formation

Radiography of the hip bone.

Transition from traveling to standing waves in the 4:1 resonant Belousov-Zhabotinsky reaction.

Current Understanding of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Psychologic testing in evaluating and understanding organic brain damage and the effects of drugs in children.

The relationship of average backfat thickness of feedlot steers to performance Roundup 2004

Current Progress in Breast Implant-Associated Anaplastic Large Cell Lymphoma

Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research

Our Experience in Diagnosing and Treating Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Breast implant-associated anaplastic large-cell lymphoma: A series of two case reports diagnosed by cytopathology

Enhanced N2 dissociation on Ru-loaded inorganic electride.

Breast Implant-associated Anaplastic Large Cell Lymphoma - a Systematic Review with Pooled Analysis

Open loop compensation for the eddy current effect in the APS storage ring vacuum chamber

Breast implant-associated anaplastic large cell lymphoma: where hematology and plastic surgery meet

Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Why Must We Learn About It?

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Breast Implant Associated Anaplastic Large Cell Lymphoma: Evidence-Based Consensus Conference Statement From The American Association of Plastic Surgeons